Evidence map›Paper›PMID 41207922›Full record

ArticleAnnals of hematology2025

Nomogram for predicting the overall survival and disease-specific survival of adult patients with primary diffuse large B-cell lymphoma, leg type based on the SEER database.

Jing Zhou, Hanyu Wang, Dan Li, Yang Cao, Gaoxiang Wang

Abstract read
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jing Zhou *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hanyu Wang *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Dan LiDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yang CaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. caoyangemma@163.com.
Gaoxiang WangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. gxwtjxy@126.com.

Funding

National Key Research and Development Program of China 2021YFA1101500National Natural Science Foundation of China 82100221
6 · The paper itself

Abstract

Primary diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is a rare lymphoma with a poor prognosis. An accurate predictive model for the prognosis of these patients is lacking. Here, we retrospectively analyzed the clinical data of 968 adult patients who were diagnosed with PCDLBCL, LT between 2000 and 2020 obtained from the Surveillance, Epidemiology and End Results (SEER) database. Multivariate Cox regression analysis revealed that age, marital status and radiation were independent prognostic factors for overall survival (OS), while age, Ann Arbor stage and radiation were independent prognostic factors for disease-specific survival (DSS). Nomograms were constructed to predict 1-, 3- and 5-year OS and DSS. The concordance indices, receiver operating characteristic curves and calibration curves revealed that the established nomograms had good accuracy in predicting the outcomes of patients with PCDLBCL, LT. The web-based calculators were subsequently developed to provide individualized predictions for OS and DSS in patients with PCDLBCL, LT. Moreover, according to the risk scores of the nomograms, patients were divided into low-, median-, and high-risk groups. In conclusion, the nomograms and accompanying web-based survival calculators offer practical tools for individualized prediction of OS and DSS in patients with PCDLBCL, LT. Risk stratification based on these tools may assist clinicians in identifying high-risk patients and guiding optimal treatment decisions.

Indexed as

Lymphoma, Large B-Cell, DiffuseNomogramsSEER ProgramAdultAgedAged, 80 and overDatabases, FactualFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateLeg typePrimary diffuse large b-cell lymphomaRisk factorsSEERSurvival

Identifiers

PMID41207922
PMCPMC12672811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.